AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie adjusted Diluted Earnings Per Share — Non-GAAP ($/sh) ($)
Form 8-K Non-GAAP Reconciliations
Latest, Q2 2026
3.65
Period ended Jun 30, 2026
Change on a year earlier
+22.9%
2.97 in Q2 2025
History
18 quarters
Since Q1 2022
Sources
18
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up adjusted diluted earnings per share — non-gaap ($/sh)
- Reported Diluted Earnings Per Share — GAAP ($/sh)2.03 · Q2 2026
- Total Specified Items — Pre-Tax ($M)3,335 · Q2 2026
- Total Specified Items — Income Tax Impact ($M)457 · Q2 2026
- Specified Item: Intangible Asset Amortization — Pre-Tax ($M)1,689 · Q2 2026
- Specified Item: Change in Fair Value of Contingent Consideration — Pre-Tax ($M)1,518 · Q2 2026
Cite this data
StockData. (2026). AbbVie Adjusted Diluted Earnings Per Share — Non-GAAP ($/sh) ($), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/nongaap_adj_eps
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.